; (ii) 3 provider representatives, including 1 hospital representative and 1 pharmacist representative; (iii) 1 health services researcher; (iv) 1 health care economist; (v) 1 representative of a sponsor of a health plan or health insurance coverage; (vi) 1 pharmacy benefit management services representative; and (vii) 1 drug manufacturer representative. (B) Duration of terms Members appointed to the Committee under subparagraph (A) shall be appointed to serve 5-year terms, which shall be staggered for the members first appointed. (C) Term limits Members appointed to the Committee under subparagraph (A) may not be so appointed for more than 2 terms. (D) Conflicts of interest (i) In general In appointing members under subparagraph (A), the Comptroller General of the United States shall consider and disclose any potential conflicts of interest. Members of the Board shall recuse themselves or be recused from relevant Committee activities in the case where the member (or an immediate family member of such member) has a conflict of interest. (ii) Disclosure of conflicts of interest (I) In general A conflict of interest or potential conflict of interest shall be disclosed, as applicable— (aa) by the Committee, in appointing members to an advisory committee and for employment as staff on the Committee